Jefferies Assumes Cogent (COGT) at Buy, 'A Validated Tool "KIT" for Mast Cell Diseases & GI Cancer'
Tweet Send to a Friend
(Updated - April 1, 2024 3:17 AM EDT)
Jefferies analyst Kelly Shi assumes coverage on Cogent (NASDAQ: COGT) with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Jefferies analyst Kelly Shi assumes coverage on Cogent (NASDAQ: COGT) with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
